We've teamed up with leading patient engagement organisations COUCH Health and Egality Health to make Parkinson's research more accessible, relevant and inclusive.
If you test positive for coronavirus, you may be able to take part in a UK-wide trial to find out if antiviral drugs can help people recover faster.
Scientists have shown a pioneering test could diagnose Parkinson's correctly in its early stages.
We're investing in research into inflammation that could help develop drugs that slow the progression of Parkinson's, something no current medication can do.
The first participant has been recruited to a pioneering clinical trial which is testing a new drug called NLX-112 to investigate its potential for people with Parkinson's.
UCB, a global pharmaceutical company, has joined forces with Parkinson's UK, and the Parkinson's Foundation in the US, to establish a Patient Engagement Council for Parkinson's Research.
We've launched a new report, Nobody really knows us – the state of health and social care for people with Parkinson's-related dementia.
We've developed an interactive communications toolkit to help researchers in all areas of health research to keep in touch with their participants. It is supported by the Health Research Authority (HRA) as part of the Make It Public strategy.
We've invested a further £490,000 to support the development of drugs to protect mitochondria and treat Parkinson's.
Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson's.
Researchers in the United States have shown that a compound found in fruit - farnesol - has the potential to play a protective role to dopamine-producing brain cells.
Caroline Rassell has been appointed as our new Chief Executive. She brings 20 years of board experience in healthcare and government roles.
Over 30 Scottish landmarks, including Edinburgh Castle, showed their support by lighting up in the colours of Parkinson's UK
It's our mission to improve life for everybody affected by Parkinson's. To stay true to this, we must proactively tackle barriers to accessing our support and NHS services, and barriers to participating in medical research.
The latest report by the Royal College of Speech and Language Therapists shows the impact of lockdown on this vital therapy.
Research shows it's possible to identify Parkinson's based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
We're investing up to £1.2m into pioneering research in partnership with the University of Sheffield, which aims to develop a drug to protect dopamine-producing brain cells.
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson's.